COMUNICADO: Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist

Source Summary

(Información remitida por la empresa firmante) • The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain.